Biosplice Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Biosplice Therapeutics sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).

20 total trials none currently recruiting 14 completed early-phase tilt top decile by trial count

Biosplice Therapeutics: 20 sponsored US clinical trials, none currently recruiting.

Biosplice Therapeutics sponsors 20 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 5 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Androgenetic Alopecia, with 1 trials.

Top-decile sponsor footprint

Biosplice Therapeutics ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

14 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

20 total, page 1 of 1

COMPLETED Phase 3

A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

NCT05603754
TERMINATED Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

NCT05084859
TERMINATED Phase 3

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

NCT04931667
COMPLETED Phase 1

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

NCT04598542
TERMINATED Phase 3

A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

NCT04520607
COMPLETED Phase 3

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

NCT04385303
COMPLETED Phase 3

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

NCT03928184
TERMINATED Phase 2

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

NCT03706521
COMPLETED Phase 2

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03727022
TERMINATED Phase 1

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

NCT03355066
COMPLETED Phase 1

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

NCT03502434
TERMINATED Phase 1

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

NCT03246399
COMPLETED Phase 2

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03122860
COMPLETED Phase 1

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

NCT03229291
COMPLETED

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

NCT02951026
COMPLETED Phase 2

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

NCT02536833
COMPLETED Phase 2

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

NCT02503137
COMPLETED Phase 2

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT02275351
COMPLETED Phase 1

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

NCT02191761
COMPLETED Phase 1

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 6
Phase 3 5

Therapeutic Areas

Androgenetic Alopecia 1
Knee Osteoarthritis 1

How the Biosplice Therapeutics early-phase archive is shaped

20 indexed studies, none listed as recruiting (0% open); 14 completed (70%).

Phase mix: 5 late (III/IV) vs 14 early (I/II) (early-phase heavy).

Top condition: Androgenetic Alopecia (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Biosplice Therapeutics: archived-pipeline peers nationwide

Peers matched on 20 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Biosplice Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20% Total trials Recruiting share Biosplice Therapeutics59th Medical WingAbiomedAgency for Healthcare Research and Quality (AHRQ)Alliance Foundation Trials10xBio22nd Century Group23andMe3-C Institute for Social Development
Biosplice Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Biosplice Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 20 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Biosplice Therapeutics page

20 registered trials is a research-attention snapshot, not an endorsement of Biosplice Therapeutics or any single study.

  • None of Biosplice Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Androgenetic Alopecia is the condition Biosplice Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Androgenetic Alopecia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Biosplice Therapeutics pipeline card: 20 registered trials from official public datasets.Report a data error.